Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
US Army

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020240

« Back to Dashboard

NDA 020240 describes RENORMAX, which is a drug marketed by Schering and is included in one NDA. Additional details are available on the RENORMAX profile page.

The generic ingredient in RENORMAX is spirapril hydrochloride. Additional details are available on the spirapril hydrochloride profile page.

Summary for 020240


Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength3MG
Approval Date:Dec 29, 1994TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength6MG
Approval Date:Dec 29, 1994TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength12MG
Approval Date:Dec 29, 1994TE:RLD:No

Expired Orange Book Patents for NDA: 020240

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
ScheringRENORMAXspirapril hydrochlorideTABLET;ORAL020240-001Dec 29, 1994► Subscribe► Subscribe
ScheringRENORMAXspirapril hydrochlorideTABLET;ORAL020240-004Dec 29, 1994► Subscribe► Subscribe
ScheringRENORMAXspirapril hydrochlorideTABLET;ORAL020240-003Dec 29, 1994► Subscribe► Subscribe
ScheringRENORMAXspirapril hydrochlorideTABLET;ORAL020240-002Dec 29, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Federal Trade Commission
Queensland Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: